Q2 2026 Johnson & Johnson Earnings Call Transcript
Key Points
- Johnson & Johnson (JNJ) reported operational sales growth of 5.6% in Q2 2026, with sales exceeding $25 billion.
- The company raised its full-year 2026 guidance, projecting operational sales growth between 6.5% and 7.1%.
- Innovative Medicine segment delivered operational sales growth of 6.8%, driven by strong performance in oncology, immunology, and neuroscience.
- MedTech segment showed resilience with operational sales growth of 3.6%, despite challenges in cardiovascular.
- Johnson & Johnson (JNJ) has a robust pipeline with 28 products each generating over $1 billion in annual sales, positioning the company for future growth.
- STELARA faced a significant decline of 55.7% due to biosimilar competition and unfavorable patient mix.
- Abiomed's growth slowed in Q2, impacted by increased decision selectivity and procedural volume pressures.
- MedTech's cardiovascular segment underperformed expectations, particularly in heart recovery.
- The company experienced a net expense increase in other income and expense, driven by higher litigation expenses and restructuring-related costs.
- Adjusted income before tax margins for both Innovative Medicine and MedTech segments declined slightly compared to the previous year.
Good morning, and welcome to Johnson & Johnson's second-quarter 2026 earnings conference call. (Operator Instructions) This call is being recorded. (Operator Instructions)
I will now turn the conference call over to Johnson & Johnson. You may begin.
Hello, everyone. This is Ryan Koors, Vice President of Investor Relations for Johnson & Johnson. I'm excited to be here today and to lead the Investor Relations team moving forward. Welcome to our company's review of business results for the second quarter of 2026 and our financial outlook for the full year.
First, a few logistics. As a reminder, today's presentation and associated schedules are available on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position, and business strategy.
You are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
